About gh research plc - GHRS
GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
GHRS At a Glance
GH Research Plc
Joshua Dawson House
Dublin, Dublin 2
| Phone | 353-1-437-8334 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -48,258,000.00 | |
| Sector | Health Technology | Employees | 73 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GHRS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.816 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.204 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
GHRS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -661,068.493 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GHRS Liquidity
| Current Ratio | 34.126 |
| Quick Ratio | 34.126 |
| Cash Ratio | 33.497 |
GHRS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -20.255 |
| Return on Equity | -21.043 |
| Return on Total Capital | -17.222 |
| Return on Invested Capital | -21.02 |
GHRS Capital Structure
| Total Debt to Total Equity | 0.183 |
| Total Debt to Total Capital | 0.183 |
| Total Debt to Total Assets | 0.178 |
| Long-Term Debt to Equity | 0.053 |
| Long-Term Debt to Total Capital | 0.052 |